A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050 on ClinicalTrials.gov · last registry update 2020-08-17

An unusually large phase 2: 834 participants, more than double the 110 typical for the stage. The sponsor logged completion for 3 May 2018. Primary outcome, as filed: Change in HbA1c. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 834
Started: 2017-08-02
Primary completion: 2018-05-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.